ATP citrate lyase (ACLY) as a novel anti-cancer drug target for hepatocellular carcinoma

The net 5-year survival rate for patients suffering from liver cancer is less then 20 percent and the number of cases is rapidly increasing in Canada. Unfortunately, currently available oral chemotherapies can only extend median survival by 3 – 4 months making the development of new and effective drug treatments critical. The proposed study aims to pave the way for a new class of drugs to help fight liver cancer and give hope to patients suffering from this deadly disease.

Faculty Supervisor:

Paola Muti

Student:

Jaya Gautam

Partner:

Espervita Therapeutics

Discipline:

Medicine

Sector:

Medical devices

University:

Program:

Accelerate

Related projects

Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.

View all
Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects

Mitacs Partners

The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.

Government
Academic
Industry
Innovation

International

Load More

International

Load More

Join a thriving innovation ecosystem.

Subscribe to our newsletter now!

Subscribe
Canada